Main Ingredient: dabigatran etexilate mesylate

Chemical Name: β-alanine,N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridine-,ethyl ester,methanesulfonate

Structural Formula:

Molecular Formula: C₃₄H₄₁N₇O₅·CH₄O₃S

Molecular Weight: 723.86 (methanesulfonate)

               627.75 (free matter) 

This product is a capsule with the content of light yellow granules. 

Prevention of stroke and systemic embolism (SEE) in adult patients with nonvalvular atrial fibrillation (NVAF) who have one or more of the following risk factors:

· Previous stroke, transient ischemic attack or systemic embolism

· Left ventricular ejection fraction < 40%

· Symptomatic heart failure, NYHA cardiac function grade ≥ 2

· Age ≥ 75

· Age ≥ 65 years, with any of the following conditions: diabetes, coronary artery disease, or hypertension

Treatment of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and prevention of related deaths.

Prevention of recurrent deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and related deaths. 

(1) 110mg (as dabigatran etexilate), (2) 150mg (as dabigatran etexilate) 

Orally, swallow whole with water, either with or after a meal. If gastrointestinal symptoms occur, it is recommended to take this product with a meal and/or a proton pump inhibitor, such as pantoprazole. Do not open the capsule. 

Note: Please refer to the Product Manual for details.